Dynamics of Resistance Emergence to Azacitidine-based Therapies in Acute Myeloid Leukemia

Inclusion Criteria

• •be ≥18 years old,
• •have a newly diagnosed AML according to ICC 2022 criteria,
• •* patients with AML related to prior chemotherapy or radiotherapy for another cancer will be eligible,
• •* patients with MDS/AML per ICC 2022 criteria will be eligible,
• •have signed the informed consent form of the eTHEMA observatory trial
• •have ≥10% blasts on the bone marrow smear at screening,
• •have not received any treatment for AML except for hydroxyurea and/or steroids,
• •* Patients having previously received hypomethylating agents for an antecedent myelodysplastic syndrome are ineligible,
• •be eligible to AZA/VEN or AZA/IVO therapy, due to general health status,
• •have an ECOG performance status ≤ 2,
• •be planned to receive azacitidine and venetoclax (AZA/VEN) or azacitidine and ivosidenib (AZA/IVO) as frontline therapy,
• •weigh ≥ 40 kg (compliance to Loi Jardé for PB sampling),
• •have provided written informed consent obtained prior to any screening procedures